BTIG raised its price target for Vericel (NASDAQ:VCEL) to $30 from $23 after an analyst and investor event focused primarily on NexoBrid, a recently licensed burn enzymatic debridement product from MediWound. ...
BTIG raised its price target for Vericel (NASDAQ:VCEL) to $13 from $8 after the company beat consensus estimates for the fourth quarter and provided strong guidance for 2018. The stock was quoted at $11.15, up $2.80, in...